Overview

A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Cougar Biotechnology, Inc.
Treatments:
Abiraterone Acetate
Glucocorticoids